amsilarotene - CAS 125973-56-0
Catalog number: 125973-56-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H27NO3Si2
Molecular Weight:
385.61
COA:
Inquire
Description:
amsilarotene (TAC-101) is a retinobenzoic acid with potential antineoplastic activity. TAC-101 inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest.
Synonyms:
TAC-101.
MSDS:
Inquire
InChIKey:
VVTNSTLJOVCBDL-UHFFFAOYSA-N
InChI:
InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24)
Canonical SMILES:
C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C
Current Developer:
Taiho Pharma Inc.
1.Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model.
Eshima K;Fukaya S;Sugimoto A;Mori T;Yokoi H;Yamamoto Y;Sugiura S;Honda S;Masuko N;Murakami K;Yamasaki Y;Kagechika H Tumour Biol. 2009;30(1):1-7. doi: 10.1159/000189712. Epub 2009 Jan 12.
TAC-101, 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid, is a synthetic ligand for retinoic acid receptor (RAR)-alpha. Here, we demonstrate the contribution of TAC-101-induced AP-1 interference to stabilization of tumor growth. TAC-101 induced transcriptional activation of RAR, resulting in marked elevation of RARbeta, a representative retinoid response marker, and it also significantly repressed the transcriptional activity of AP-1 in JHH-7 cells. In contrast to JHH-7, JHH-6 is another RARalpha-expressing human hepatocellular carcinoma (HCC) cell line with constitutive activation of AP-1, but it is retinoid insensitive and did not respond to the TAC-101-induced RAR signal. TAC-101 did not inhibit AP-1 activity of the JHH-6 cell line, showing that AP-1 interference by TAC-101 must be in parallel with RAR activation. Interleukin-8 (IL-8), one of the AP-1-regulated factors which correlate with a poor prognosis in HCC patients, was found to be overexpressed in JHH-7 cells. TAC-101 reduced IL-8 production without cytotoxicity and inhibited the progression of HCC in the orthotopic mouse model with decreased tumor IL-8 level. These results suggest that downregulation of the extracellular biomarker for AP-1 interference via the induction of retinoid signals will enhance the pharmacological effect of TAC-101 on HCC and it could be useful as a surrogate biomarker of therapeutic efficacy.
2.A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S;Suzuki N;Ohie S;Higashiguchi A;Hosoi F;Kitazato K;Susumu N;Aoki D Gynecol Oncol. 2008 Mar;108(3):627-31. Epub 2007 Nov 28.
OBJECTIVE: ;A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma.;METHODS: ;Induction of genes related to apoptosis by TAC-101 or cisplatin was assessed by DNA microarray analysis. TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. The antitumor effect was evaluated by calculating the treated/control tumor volume ratio at 21 days after implantation. The histoculture drug response assay was also performed using fresh surgical specimens of human ovarian cancer to determine the 50% inhibitory concentration (IC50).;RESULTS: ;Different apoptosis-related genes were induced by TAC-101 and cisplatin. Compared with control mice, the volume of both RMG-I and RMG-II tumors was significantly reduced (p<0.05) by either drug. The IC50 values of cisplatin and TAC-101 showed a significant correlation (p<0.01).;CONCLUSION: ;These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma.
3.TAC-101, a novel retinobenzoic-acid derivative, enhances gap junctional intercellular communication among renal epithelial cells treated with renal carcinogens.
Miyaguchi T;Nomata K;Noguchi M;Watanabe J;Satoh H;Kanetake H Anticancer Res. 2001 Nov-Dec;21(6A):4025-30.
[4-3,5-Bis(trimethylsilyl)benzamido] benzoic acido] (TAC-101), which exhibits an anti-tumor effect, can bind to retinoic acid receptors (RARs). It has retinoid-like properties, such as chemopreventive action against cancer cells. The up-regulation of connexin (Cx) expression by retinoids is well known in various epithelial cells. In this study, we investigated whether TAC-101 up-regulates gap junctional intercellular communication (GJIC) in renal epithelial cells exposed to the renal carcinogens. Madin Darby canine kidney (MDCK) cells were incubated with TAC-101 for 3 days, then briefly exposed to renal carcinogens potassium bromate (KBrO3) or dimethylnitrosamine (DMN). TAC-101 increased the expression of connexin 43 protein without affecting Cx43 phosphorylation and prevented inadequate Cx43 localisation caused by KBrO3 or DMN. Consequently, TAC-101 prevented the disruption of GJIC in MDCK cells. These data suggested that TAC-101 enhanced GJIC by up-regulating Cx43 expression and that TAC-101 might be useful for the prevention of renal cell carcinoma.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1174130-61-0 LY-2456302

LY-2456302
(CAS: 1174130-61-0)

LY-2456302, also called as CERC-501, is a potent, highly selective and centrally-penetrant kappa opioid receptor antagonist(Ki= 0.807 nM)with favorable pharmaco...

CAS 7632-00-0 Sodium Nitrite

Sodium Nitrite
(CAS: 7632-00-0)

Sodium nitrite is a myeloperoxidase inhibitor with IC50 of 1.3 μM.

CAS 461054-93-3 Ko 143

Ko 143
(CAS: 461054-93-3)

Ko 143 is a potent and selective inhibitor of BCRP, preventing the export of mitoxantrone and topotecan in breast cancer cell lines. It is much less effective a...

CAS 688737-95-3 TP-110

TP-110
(CAS: 688737-95-3)

TP-110 is a new proteasome inhibitor, which shows potent growth inhibition in various tumor cell lines. Treatment with TP-110 for 24 h in vitro induced apoptosi...

CAS 367909-40-8 MRS 2279

MRS 2279
(CAS: 367909-40-8)

MRS 2279 is the first broadly applicable, selective and high affinity competitive antagonist radioligand for a P2Y receptor (Ki = 2.5 nM; IC50 = 51.6 nM).

CAS 174635-53-1 SB 218795

SB 218795
(CAS: 174635-53-1)

SB 218795 is a potent and competitive non-peptide NK3 receptor antagonist (Ki = 13 nM at hNK3) displaying 90-fold and 7000-fold selectivity over hNK2 and hNK1 r...

V5 Epitope Tag Peptide

V5 Epitope Tag Peptide, a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5, is used as a blocking...

CAS 100872-83-1 ML346

ML346
(CAS: 100872-83-1)

ML346, a barbituric acid skeleton compound, is a novel activator of Hsp70 which could induce HSF-1-dependent chaperone expression and repair protein folding in ...

Chemical Structure

CAS 125973-56-0 amsilarotene

Quick Inquiry

Verification code

Featured Items